Argenx Halts Phase 3 Sjögren's Study on Interim Data

Argenx discontinued its Phase 3 'Unity' trial of efgartigimod for Sjögren's Syndrome after an independent data monitoring committee recommended stopping based on interim efficacy results. Safety was not cited as a concern. The failure removes a potential near-term treatment option for Sjögren's and may pressure Argenx's pipeline outlook.